DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma

Oncology Letters

Volumn 6, Issue 6, 2013, Pages 1624-1630

  Ma, Jianjuan ^a   Yu, Xiying ^a   Guo, Liping ^a   Lu, Shih Hsin ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Apoptosis; Differentiation; Dual specificity phosphatase 6; Esophageal squamous cell carcinoma; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DUAL SPECIFICITY PHOSPHATASE 6; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADULT; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR BIOPSY; UPREGULATION; WESTERN BLOTTING;

EID: 84886800634     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1605     Document Type: Article

References (43)

1. Arkell RS, Dickinson RJ, Squires M, Hayat S, Keyse SM and Cook SJ: DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5. Cell Signal 20: 836-843, 2008.
2. Eblaghie MC, Lunn JS, Dickinson RJ, et al: Negative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryos. Curr Biol 13: 1009-1018, 2003.
3. Lewis TS, Shapiro PS and Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139, 1998.
4. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001.
5. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002.
6. Ekerot M, Stavridis MP, Delavaine L, et al: Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem J 412: 287-298, 2008.
7. Nichols A, Camps M, Gillieron C, et al: Substrate recognition domains within extracellular signal-regulated kinase mediate binding and catalytic activation of mitogen-activated protein kinase phosphatase-3. J Biol Chem 275: 24613-24621, 2000.
8. Muda M, Theodosiou A, Gillieron C, et al: The mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity. J Biol Chem 273: 9323-9329, 1998.
9. Zhou B, Wu L, Shen K, Zhang J, Lawrence DS and Zhang ZY: Multiple regions of MAP kinase phosphatase 3 are involved in its recognition and activation by ERK2. J Biol Chem 276: 6506-6515, 2001.
10. Sridhar SS, Hedley D and Siu LL: Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4: 677-685, 2005.
11. Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med 38: 200-211, 2006.
12. Furukawa T, Yatsuoka T, Youssef EM, et al: Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Cytogenet Cell Genet 82: 156-159, 1998.
13. Furukawa T, Sunamura M, Motoi F, Matsuno S and Horii A: Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 162: 1807-1815, 2003.
14. Furukawa T, Fujisaki R, Yoshida Y, et al: Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol 18: 1034-1042, 2005.
15. Xu S, Furukawa T, Kanai N, Sunamura M and Horii A: Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet 50: 159-167, 2005.
16. Okudela K, Yazawa T, Woo T, et al: Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol 175: 867-881, 2009.
17. Chan DW, Liu VW, Tsao GS, et al: Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29: 1742-1750, 2008.
18. Croonquist PA, Linden MA, Zhao F and Van Ness BG: Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood 102: 2581-2592, 2003.
19. Bloethner S, Chen B, Hemminki K, et al: Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26: 1224-1232, 2005.
20. Ramnarain DB, Park S, Lee DY, et al: Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 66: 867-874, 2006.
21. Messina S, Frati L, Leonetti C, et al: Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene 30: 3813-3820, 2011.
22. Warmka JK, Mauro LJ and Wattenberg EV: Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras. J Biol Chem 279: 33085-33092, 2004.
23. Cui Y, Parra I, Zhang M, et al: Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 66: 5950-5959, 2006.
24. Chiappinelli KB, Rimel BJ, Massad LS and Goodfellow PJ: Infrequent methylation of the DUSP6 phosphatase in endometrial cancer. Gynecol Oncol 119: 146-150, 2010.
25. No authors listed: Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol 5: 517-526, 2008.
26. Leung AC, Wong VC, Yang LC, et al: Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer 122: 587-594, 2008.
27. Wang Y, Fan H, Zhou B, et al: Fusion of human umbilical cord mesenchymal stem cells with esophageal carcinoma cells inhibits the tumorigenicity of esophageal carcinoma cells. Int J Oncol 40: 370-377, 2012.
28. Han Y, Wei F, Xu X, et al: Establishment and comparative genomic hybridization analysis of human esophageal carcinomas cell line EC9706. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19: 455-457, 2002 (In Chinese).
29. Shimada Y, Imamura M, Wagata T, Yamaguchi N and Tobe T: Characterization of 21 newly established esophageal cancer cell lines. Cancer 69: 277-284, 1992.
30. Li LW, Yu XY, Yang Y, Zhang CP, Guo LP and Lu SH: Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer 125: 1505-1513, 2009.
31. Li C, Scott DA, Hatch E, Tian X and Mansour SL: Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. Development 134: 167-176, 2007.
32. Furukawa T and Horii A: Molecular pathology of pancreatic cancer: in quest of tumor suppressor genes. Pancreas 28: 253-256, 2004.
33. Shimada Y, Sato F, Watanabe G, et al: Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patient's prognosis and smoking history. Cancer 89: 5-11, 2000.
34. Zhu YH, Fu L, Chen L, et al: Downregulation of the novel tumor suppressor DIRAS1 predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Res 73: 2298-2309, 2013.
35. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116, 2006.
36. Feinberg AP, Ohlsson R and Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33, 2006.
37. Wong VC, Chen H, Ko JM, et al: Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer 130: 83-95, 2012.
38. Rössig L, Haendeler J, Hermann C, et al: Nitric oxide down-regulates MKP-3 mRNA levels: involvement in endothelial cell protection from apoptosis. J Biol Chem 275: 25502-25507, 2000.
39. Zhang Z, Kobayashi S, Borczuk AC, et al: Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31: 577-586, 2010.
40. Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J and Van Obberghen-Schilling E: The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell 11: 1103-1112, 2000.
41. Bonni A, Brunet A, West AE, Datta SR, Takasu MA and Greenberg ME: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. Science 286: 1358-1362, 1999.
42. Erhardt P, Schremser EJ and Cooper GM: B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19: 5308-5315, 1999.
43. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.